Articles tagged with Autoimmune Disorders
Researchers at Utrecht University found an extremely broad variety of autoantibodies in RA patients, contradicting previous assumptions about the disease. The study suggests that targeting the malfunctioning filtering mechanism may be a better approach to treat RA.
Researchers revealed the biological mechanisms by which class II HDACs activate Th17 cell differentiation, leading to inflammation. A potent inhibitor, TMP269, was found to influence Th17 cell differentiation in a mouse model of ulcerative colitis, providing potential therapeutic approach for IBD treatment.
Researchers have developed a statistical method called SCENT to establish links between regulatory elements and genes, pinpointing probable causal gene loci for common and rare diseases. The study applied SCENT to multimodal single-cell datasets from various human tissues, discovering insights into DNA regulation in specific cell types.
Climate change, pollution, and biodiversity loss are damaging our immune systems, increasing the risk of diseases like asthma and cancer. Improving the environment offers effective protection and can have a powerful return on investment, saving $3 in healthcare costs for every $1 spent on mitigation.
Researchers at Mayo Clinic have developed an immunotherapy strategy that combines chimeric antigen receptors with mesenchymal stromal cells, known as CAR-MSCs. This approach shows potential in targeting inflammatory disease sites more precisely and improving immunosuppression and healing outcomes for autoimmune diseases.
A study published in Genome Medicine uses digital twins to computationally treat thousands of medications in individual patients with autoimmune diseases, finding promising results in mice and human tissue samples. The technology has the potential to revolutionize precision medicine by providing tailored medication for each patient.
Researchers found that gut bacteria in newborns produce serotonin, promoting the development of immune cells called Tregs. This helps prevent allergic reactions and autoimmune diseases. The study suggests that unique gut bacteria may supply neurotransmitters needed for critical biological functions during early development.
Researchers have identified a subset of T-cells that acts like stem cells and continuously generates effector T-cells that attack transplanted organs. Targeting the transcription factor IRF4 may lead to innovative therapies for patients with chronic infections, cancers, autoimmune diseases and transplanted organs.
Researchers found that STAP-1 plays a crucial role in activating T cells, which are white blood cells critical to defending against infections and maintaining overall health. The study suggests that STAP-1 may be involved in the development of immune disorders such as multiple sclerosis and asthma.
A recent study found that many people with type 2 diabetes know little about their condition, highlighting the need to improve communication and disease knowledge. The study revealed significant gaps in knowledge, particularly regarding blood sugar monitoring and late-stage complications like ketoacidosis.
A new study from EPFL reveals how the CRL5–SPSB3 ubiquitin ligase targets and degrades nuclear cGAS, preventing it from mistakenly attacking the body's own tissues. This regulation ensures a sophisticated balance between immune readiness and protecting the integrity of the cell's genome.
Researchers at UMass Amherst have identified PRMT5 as a key regulator of suppressive activity in immune cells, which can be trained to correct overzealous immune responses. This discovery may lay the foundation for drug-free, side-effect-free treatments for patients with autoimmune disorders such as aplastic anemia.
Researchers have identified a new therapeutic option for patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease. Benralizumab has been shown to be non-inferior to mepolizumab in reducing exacerbations and providing disease remission, with the added benefit of reduced oral corticosteroid use.
Scientists identify chronic ER stress and mitochondrial damage in DM2 cells, triggering an antiviral response and autoimmune diseases. The study provides new therapeutic targets to suppress the development of autoimmune diseases in patients.
Researchers have discovered a previously unknown mechanism behind immune tolerance, where B cells teach T cells to ignore the body's own proteins. This failure can lead to autoimmune diseases such as Multiple Sclerosis-like Neuromyelitis optica.
Researchers have found a new potential therapeutic target for autoimmune diseases such as lupus and multiple sclerosis by identifying an overlooked sequence in the IκBζ protein. This sequence, known as the OCA peptide, can activate key proteins in immune cells and may help reeling in immune cells gone haywire.
A study of over 250 patients with Cushing's disease and nonfunctioning pituitary adenomas found that those who achieved remission were more likely to develop new-onset autoimmune disease within three years. Higher prevalence of adrenal insufficiency may have contributed to this development.
Researchers from Pusan National University discovered a link between diabetes and periodontitis, showing pro-inflammatory cytokines rise in classical monocytes. The study highlights the systemic impact of these conditions on immune regulation and suggests a potential therapeutic target to reduce diabetes risk.
A new computational biology tool has analyzed the complex biological networks of multiple sclerosis patients, revealing relationships between genes, proteins, cells, brain function, and behavior. The study identified correlations between protein MK03 and immune system cell counts, retinal nerve fiber thickness, and gait test results.
Researchers have found that some tumors release a protein with a virus-like structure, triggering an out-of-control immune reaction that can damage brain cells. The immune system targets this protein as if it were a foreign invader, leading to rapid-onset memory loss and cognitive deficits.
A study published in Lancet eClinical Health found pregnancy outcomes for pregnant individuals with autoimmune disease vary greatly depending on the specific condition and individual factors. Research highlights the importance of considering comorbidities when discussing autoimmune disease and pregnancy.
Researchers at the University of Freiburg discovered that defective signalling pathways play a decisive role in immune cell development, leading to problems with B cell maturation and function. This finding opens up new therapeutic approaches for autoimmune diseases like ALPS.
Researchers from Scripps Research have developed a small molecule that blocks the activity of SLC15A4, a protein linked to autoimmune diseases like lupus and Crohn's disease. The compound, FFF-21, successfully reduced inflammation in mouse models and isolated cells from people with lupus.
A study published in Cell Genomics reveals that specific changes in CD4+ T cell categories and gene programs are associated with autoimmune diseases, including distinct patterns related to aging and sex. The findings provide a comprehensive catalog of CD4+ T cell changes linked to 20 different autoimmune diseases.
The University of Rochester is establishing a new NIH-funded center focused on developing FDA-qualified drug development tools related to barrier functions in disease. Researchers will create microphysiological systems with ultrathin membranes of human cells, aiming to reduce animal trials and improve drug efficacy.
Women with autoimmune disease are 30% more likely to experience perinatal depression, while those with perinatal depression have a 30% higher risk of developing an autoimmune disease. The strongest association is seen with multiple sclerosis.
A team of international researchers has reported the first high-resolution images and structural details of the human genetic element LINE-1, which is implicated in various diseases. The study provides a target for potential new treatments, particularly for cancer, autoimmune disorders, neurodegeneration, and even aging.
Gladstone scientists have created an intricate map of how the immune system functions, examining the detailed molecular structures governing human T cells. This study will accelerate the development of new and better therapies for cancer and autoimmune diseases.
Research led by Professor John McGrath found no association between neonatal protein C4 and risk of mental disorders, but a link was discovered between higher C3 concentration and reduced schizophrenia risk in women. The study also found strong genetic links with several autoimmune disorders.
A new method developed at Karolinska Institutet can identify unique immune cell receptors and their location in human tissue. This breakthrough could lead to the development of novel therapies for diseases such as cancer and autoimmune disorders, by pinpointing the specific immune cells responsible.
A previously unknown function of the DECTIN-1 protein has been discovered, which exacerbates severe autoimmune diseases in its mutated state. The researchers believe they can control the immune system by turning the protein on and off, offering new treatment options for autoimmune disease and cancer.
Researchers discovered distinct mechanisms controlling different types of immune cells and found a way to selectively eliminate 'problematic' cells driving autoimmune disorders. This breakthrough offers precise targets for potential treatment strategies, potentially revolutionizing the way we treat skin conditions.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
Researchers have successfully mapped the entire HLA class II landscape, predicting how pathogens are displayed on cell surfaces. The mapping reveals that multiple HLA variants play essential roles in autoimmune disorders and organ rejection, highlighting their potential for developing immunotherapy treatments.
Salk researchers identify Foxp3 as the protein that determines regulatory T cell genome structure and fate, enabling manipulation to treat autoimmunity or fight cancer. The study reveals Foxp3's essential role in creating unique chromatin architecture of regulatory T cells.
A groundbreaking study sheds light on the intricate mechanism behind the immune system's ability to differentiate between self and non-self antigens. Continuous activation of self-reactive T cells is essential for maintaining equilibrium and self-tolerance through regulatory T cells.
A study found that people with a specific genetic mutation in the CARD9 gene have higher IL-17 protein levels, making them more responsive to IL-17 inhibitor biologics. This discovery may lead to targeted treatment recommendations for ankylosing spondylitis patients.
Researchers identified TLR9 as a key receptor in central tolerance, the process that eliminates self-reactive B cells. Depleting TLR9 impairs this process, leading to increased antibody production and autoimmune disease. Neutralizing CXCL4 may restore B cell tolerance, offering new therapeutic strategies.
Researchers at Regenstrief Institute and Indiana University School of Dentistry linked electronic dental and health records to provide better care for individuals with Sjögren's disease. This can lead to earlier diagnosis and treatment, reducing the impact of tooth decay and improving overall health.
Research identifies immunosuppressed individuals with lower antibody prevalence after three or more COVID-19 vaccine doses, highlighting increased vulnerability to severe infection. The MELODY study found that around one in five people with compromised immune systems had no COVID-19 antibodies.
Researchers discovered cytoplasmic retinoic acid receptors, such as RARalpha, are essential for T cell linking sensing at the cell surface with downstream signaling cascades and gene expression programs. The study sheds new light on TCR signaling and its connection to cancer treatment.
A new study found that around one in five people with compromised immune systems have no COVID-19 antibodies after three or more vaccinations. The MELODY study identified specific groups at higher risk of not producing antibodies, highlighting the need for targeted interventions and booster vaccines.
Researchers at Brigham and Women's Hospital have designed a probiotic to suppress autoimmunity in the brain, which is at the core of several diseases including MS. The treatment offers a more precise way to target brain inflammation with reduced negative side effects compared to standard therapies.
A new Harvard-led research suggests that the thymus, often considered expendable in adults, actually plays a crucial role in maintaining adult immune health and preventing cancer. The study found that patients who had their thymus removed had a nearly threefold higher risk of death from various causes, including cancer.
A study from the University of Gothenburg found that even vulnerable people with compromised immune systems achieved good antibody levels after three doses of COVID-19 mRNA vaccine. This is particularly significant for those at risk of severe Covid-19, as they showed catch-up antibody responses and high levels of hybrid immunity.
A large study found a significant link between vitamin D levels and psoriasis severity, with lower levels associated with greater severity. The research suggests that a vitamin D-rich diet or oral supplementation may provide benefits for individuals with psoriasis.
Researchers from Osaka University found that RNase treatments can either enhance or weaken immune activation in systemic autoimmune diseases. The study suggests that the composition of immune complexes plays a crucial role in determining the effectiveness of RNase treatment.
The new Clinical Research Unit will investigate autoantibodies' role in neurological disorders, focusing on diagnosis and treatment. Researchers expect innovative therapies for patients with previously suspected diseases.
Professor Coppedè's appointment aims to enhance the journal's focus on cutting-edge genomics research, covering topics like genome sequencing and functional genomics. He will lead Current Genomics to greater success by staying at the forefront of genomics discoveries and advancements.
A study of over 22,000 people with MS discovered the first genetic variant associated with faster disease progression, which can rob patients of mobility and independence. Understanding this variant will hopefully pave the way for new treatments that can prevent disease progression.
Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.
Researchers in Austria found that one in three patients with Type 2 diabetes stopped treatment and monitoring for at least a year, resulting in higher mortality rates. This group had a significantly higher mortality rate compared to those who regularly accessed care.
A study published in Brain Behavior and Immunity found autoantibodies against a synaptic adhesion protein, neurexin 1α, in patients with schizophrenia. In mice, these autoantibodies caused schizophrenia-related changes, including reduced social behavior and cognitive function.
Researchers found variability in IgA levels between blood and gut samples, suggesting IgA regulates commensal microbes to prevent immune dysregulation. Patients with normal fecal IgA were less likely to develop symptoms, while those deficient in both blood and fecal IgA showed elevated inflammatory cytokines.
Researchers found specific HLA molecules linked to MPO-AAV susceptibility and increased risk of relapse, potentially leading to precision medicine solutions for treatment. Biomarkers may be developed to predict relapse risk, improving patient outcomes.
A recent study published in the Journal of Clinical Immunology suggests that cutaquig infusions at higher infusion rates and volumes are well-tolerated and effective, with reduced infusion time, fewer injection sites, and improved compliance. The study results will be presented at the Clinical Immunology Society 2023 Annual Meeting.
A new study published in Science Advances has found that certain antibodies against the Epstein-Barr virus can mistakenly target the brain and spinal cord, causing damage in multiple sclerosis patients. The research reveals a potential link between EBV infection and MS, with implications for personalized therapies.
Researchers at NIH have characterized idiopathic CD4 lymphocytopenia, a rare immune deficiency that affects the body's ability to fight off infections. People with severe cases of ICL are at higher risk of acquiring or developing multiple diseases, including cancers and autoimmune disorders.
Dr. Roland Martin is honored for his work on immune mechanisms underlying multiple sclerosis, identifying key genes and nerve-insulating components targeted by immune attacks. His experimental therapy aims to make the immune system ignore those targets while preserving protective immunity.
A UC Riverside-led study found that reduced PTPN2 activity in intestinal epithelial cells leads to decreased Paneth cell antimicrobial peptide production, disrupting the gut microbiota and increasing E. coli. This loss can serve as a marker of IBD disease.